Acadia - Catalysts Stacking, page-41

I listened to the RBC Healthcare conference with Acadia Pharmaceuticals. The VP sounded confident they were still on track for a mid year NDA submission. It was interesting listening to the high hopes they had for the sNDA for nuplizaid. I understand the rationale for going after ADP, a 5x bigger market than PDP would’ve brought in very substantial revenues but the FDA thought otherwise.

Admittedly, after the initial rejection from the FDA I was concerned whether Acadia with its current management team was the right fit for Neuren. I was reassured somewhat after listening to the conference Acadia will ultimately make a good partner, but with the rejection it also highlights the risks partnering with one company where ROW rights are concerned. I’d be surprised if Acadia wins ROW rights, they became an outright competitor (perhaps it was already in the offing) when they partnered with Stoke. My hope is Neuren hedges it’s bets and gives itself a couple of options.